Soleno Therapeutics

$2.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-4.74%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell SLNO and other stocks, options, and ETFs commission-free!

About SLNO

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA. The listed name for SLNO is Soleno Therapeutics, Inc. Common Stock.

CEO
Anish Bhatnagar
Employees
25
Headquarters
Redwood City, California
Founded
1999
Market Cap
202.49M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
307.05K
High Today
$2.59
Low Today
$2.41
Open Price
$2.55
Volume
201.37K
52 Week High
$4.39
52 Week Low
$1.30

SLNO News

BenzingaFeb 23

Soleno Therapeutics, Vanderbilt University In Research Pact For K Channel Activators

Soleno Therapeutics Inc (NASDAQ: SLNO) has signed a collaboration agreement with Vanderbilt University for the discovery and development of KATP channel activat

SLNO Earnings

-$0.36
-$0.23
-$0.10
$0.03
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 12, After Hours

You May Also Like

DBOEY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure